Halozyme Therapeutics (HALO) appoints Dannielle Appelhans to its board
Rhea-AI Filing Summary
Halozyme Therapeutics, Inc. (HALO) reported a board change. On August 14, 2026, Dannielle Appelhans was elected to the company’s Board of Directors. She joins the class of directors whose terms end at the 2028 annual meeting of stockholders and was not initially assigned to any board committee.
Appelhans will receive cash retainers plus restricted stock and stock option awards under Halozyme’s standard director compensation program for non-employee directors, as previously described in the proxy statement for the 2026 annual meeting held on May 5, 2026. The company states there are no special arrangements related to her election and no related person transactions with her.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Election date: August 14, 2026
Term end: 2028
2026 Annual Meeting date: May 5, 2026
3 metrics
Election date
August 14, 2026
Date Dannielle Appelhans was elected to the Board of Directors
Term end
2028
Year of the annual meeting at which her director term ends
2026 Annual Meeting date
May 5, 2026
Date of the 2026 Annual Meeting where the director compensation program was described
Key Terms
non-employee directors, director compensation program, related person transactions, annual meeting of stockholders
4 terms
non-employee directors regulatory
"our director compensation program applicable to all non-employee directors"
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
director compensation program financial
"under our director compensation program applicable to all non-employee directors"
annual meeting of stockholders regulatory
"at the Company’s annual meeting of stockholders in 2028"
FAQ
What board change did HALOZYME THERAPEUTICS, INC. (HALO) announce in this 8-K?
Halozyme Therapeutics announced that Dannielle Appelhans was elected to its Board of Directors on August 14, 2026. She joins the director class whose terms end at the 2028 annual meeting and was not initially assigned to any board committee.
When does Dannielle Appelhans’ board term at HALO end?
Dannielle Appelhans was elected to the Halozyme board in a class of directors with terms ending at the 2028 annual meeting. She will serve until that meeting, consistent with the company’s classified board structure for that director class.
How will the new HALO director be compensated for board service?
Dannielle Appelhans will receive compensation under Halozyme’s standard non-employee director compensation program, including cash retainers for board and committee service, and awards of restricted stock and stock options, as described in the 2026 proxy statement.
Are there any special arrangements linked to Dannielle Appelhans’ election to HALO’s board?
Halozyme states there are no arrangements or understandings pursuant to which Dannielle Appelhans was elected as a director. The company also reports there are no related person transactions between Halozyme and Appelhans.
Where did HALO previously describe its non-employee director compensation program?
Halozyme indicates that the current components of its non-employee director compensation program were described in its proxy statement for the 2026 Annual Meeting of Stockholders, which was held on May 5, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Ms. Appelhans was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2028 and was not initially assigned to any Board committee. Ms. Appelhans will receive compensation for her services (currently consisting of cash retainers for Board and committee service, restricted stock and stock option awards) under our director compensation program applicable to all non-employee directors, as revised from time to time. The current components of the non-employee director compensation program were described in our proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026.
There are no arrangements or understandings pursuant to which Ms. Appelhans was elected as a director and there are no related person transactions between the Company and Ms. Appelhans.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc (Registrant) | |||||||||||||||||
Dated: | August 18, 2026 | By: | /s/ Mark Snyder | ||||||||||||||
| Mark Snyder | |||||||||||||||||
| Executive Vice President, General Counsel and Corporate Secretary | |||||||||||||||||